Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson shockwave (intravascular lithotripsy) sub-franchise — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
325
Period ended Sep 30, 2026
Change on a year earlier
+16.9%
278 in Q3 2025
History
14 quarters
Since Q2 2023
Sources
9
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Shockwave (intravascular lithotripsy) sub-franchise — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 325 | +16.9% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 335 | +14.7% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 305 | +18.2% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 318 | +23.3% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 278 | +21.4% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 292 | +279.2% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 258 | – | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 258 | – | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 229 | – | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 77 | – | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | – | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 0 | – | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 0 | – | Form 10-Q (filed 2024-07-25) ↗ |
Breakdown
What makes up shockwave (intravascular lithotripsy) sub-franchise — worldwide sales ($m)
- Shockwave (intravascular lithotripsy) sub-franchise — U.S. sales ($M)261 · Q3 2026
- Shockwave (intravascular lithotripsy) sub-franchise — International sales ($M)64 · Q3 2026
- Shockwave (intravascular lithotripsy) sub-franchise — Worldwide reported growth YoY (%)16.8% · Q3 2026
- Shockwave (intravascular lithotripsy) sub-franchise — Worldwide operational (constant-currency) growth YoY (%)17.2% · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Shockwave (intravascular lithotripsy) sub-franchise — Worldwide sales ($M) ($M), quarterly Q2 2023–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt_shockwave
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.